BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 …
Over the last 12 months, insiders at BridgeBio Pharma, Inc. have bought $0 and sold $155.68M worth of BridgeBio Pharma, Inc. stock.
On average, over the past 5 years, insiders at BridgeBio Pharma, Inc. have bought $2M and sold $139.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $100,680 was made by Ellis Andrea () on 2022‑03‑15.
2024-11-19 | Sale | Chief Executive Officer | 27,389 0.0145% | $22.41 | $613,826 | 0.00% | ||
2024-11-19 | Sale | Secretary, Treasurer & CFO | 4,156 0.0022% | $22.41 | $93,137 | 0.00% | ||
2024-09-13 | Sale | 10 percent owner | 5.8M 3.0339% | $25.75 | $149.35M | -3.06% | ||
2024-08-19 | Sale | Chief Executive Officer | 27,389 0.0143% | $24.69 | $676,256 | +1.39% | ||
2024-08-19 | Sale | Secretary, Treasurer & CFO | 4,155 0.0022% | $24.69 | $102,590 | +1.39% | ||
2024-06-04 | Sale | director | 1,500 0.0009% | $31.30 | $46,950 | -4.64% | ||
2024-06-03 | Sale | director | 1,000 0.0005% | $28.84 | $28,843 | -10.63% | ||
2024-03-01 | Sale | director | 2,500 0.0014% | $34.00 | $85,000 | -24.45% | ||
2024-02-15 | Sale | director | 2,915 0.0018% | $37.75 | $110,041 | -30.95% | ||
2024-01-16 | Sale | director | 2,915 0.0017% | $37.97 | $110,683 | -25.90% | ||
2023-12-26 | Sale | director | 100,000 0.0575% | $42.06 | $4.21M | -34.09% | ||
2023-12-18 | Sale | director | 2,000 0.0012% | $40.00 | $80,000 | -27.48% | ||
2023-12-15 | Sale | director | 2,915 0.0015% | $36.12 | $105,290 | -28.49% | ||
2023-12-01 | Sale | director | 2,500 0.0014% | $29.40 | $73,500 | -8.13% | ||
2023-11-17 | Sale | CEO and President | 51,552 0.0296% | $29.10 | $1.5M | -2.59% | ||
2023-11-17 | Sale | Secretary, Treasurer & CFO | 22,685 0.013% | $29.10 | $660,059 | -2.59% | ||
2023-11-15 | Sale | director | 2,915 0.0017% | $30.00 | $87,450 | -4.34% | ||
2023-09-05 | Sale | director | 2,500 0.0016% | $30.00 | $75,000 | -3.76% | ||
2023-08-17 | Sale | CEO and President | 51,552 0.0322% | $28.59 | $1.47M | +0.92% | ||
2023-08-17 | Sale | Secretary, Treasurer & CFO | 22,683 0.0142% | $28.59 | $648,455 | +0.92% |
KKR Genetic Disorder L.P. | 10 percent owner | 25260971 13.3663% | $23.39 | 1 | 3 | +7.23% |
STEPHENSON BRIAN C | Secretary, Treasurer & CFO | 93758 0.0496% | $23.39 | 2 | 27 | +7.23% |
Scott Randal W. | director | 4000 0.0021% | $23.39 | 1 | 6 | |
Valantine Hannah | director | 1764 0.0009% | $23.39 | 2 | 4 | <0.0001% |
VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 26620991 14.0859% | $23.39 | 1 | 0 | +6.17% |